NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00930033,Clinical Trial to Assess the Importance of Nephrectomy,https://clinicaltrials.gov/study/NCT00930033,CARMENA,COMPLETED,The study compare the standard treatment with nephrectomy + sunitinib to treatment with sunitinib alone without nephrectomy. This study will be the first trial on this competitive context,NO,Metastatic Renal Cell Carcinoma,PROCEDURE: Nephrectomy|OTHER: Sunitinib alone,"The primary endpoint is overall survival., starting at 4 months","Objective Response (complete or partial) is evaluated according to RECIST 1.1 criteria, Starting at 4 months|Clinical benefit (complete response, partial or stable for at least 12 weeks)., Starting at 4 months|Progression-Free Survival, Starting at 4 months|Non-compliance to Sunitinib treatment is evaluated in arm A (nephrectomy + sunitinib) as the percentage of patients not starting sunitinib treatment within 6 weeks after nephrectomy, Starting at 4 months|Non-compliance to sunitinib treatment is evaluated in arm B (sunitinib alone) as the percentage of patients needing nephrectomy, Starting at 4 months|Post operative morbidity is evaluated as the percentage of deaths within 30 days following nephrectomy, Starting at 4 months",,Assistance Publique - HÃ´pitaux de Paris,Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE3,452,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,P070144,2009-09-09,2018-10-22,2018-10-22,2009-06-30,,2021-04-14,"Hopital Necker, Paris, 75015, France",
